EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSOMEG00000015746
Gene Symbol: GRIK4
3 Cross references
248 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSOMEG00000015786
Gene Symbol: GRIK5
3 Cross references
232 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSOMEG00000011348
Gene Symbol: GRIK5
3 Cross references
229 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSOMEG00000013796
Gene Symbol: GRM2
1 Cross references
206 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSOMEG00000012281
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSOMEG00000005033
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSOMEG00000001682
Gene Symbol: LOC112141341
3 Cross references
249 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSOMEG00000003955
Gene Symbol: LOC112138865
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSOMEG00000002214
Gene Symbol: LOC112142662
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSOMEG00000014685
Gene Symbol: LOC112163519
3 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSOMEG00000021095
Gene Symbol: LOC112137361
2 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSOMEG00000011220
Gene Symbol: LOC112143415
2 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).